MAPT and Alzheimer disease: Risk for AD, Parkinson’s disease, and other dementing disorders is elevated in the context of metabolic disturbance [11,12,13], which accelerates beta-amyloid deposition and tau hyperphosphorylation, characteristic neuropathological features of AD [14].